Gamifant for Primary Hemophagocytic Lymphohistiocytosis

Episode 8: Stay in Sync with Innovations in Medication Decision Support

FDA Approves Sotagliflozin For Heart Failure Across Full Range of LVEF

FDA Approves First Oral Treatment for Patients With Moderate to Severe Crohn's Disease

FDA Approves Two Medications for Treatment of Schizophrenia

FDA Approves Qalsody, First-of-its-Kind Treatment for Rare Form of ALS

Miebo, First Prescription Eye Drop to Treat Tear Evaporation in Dry Eye Disease, Now Available

Episode 8: Stay in Sync with Innovations in Medication Decision Support

FDA Approves Sotagliflozin For Heart Failure Across Full Range of LVEF

FDA Approves First Oral Treatment for Patients With Moderate to Severe Crohn's Disease

FDA Approves Two Medications for Treatment of Schizophrenia

FDA Approves Qalsody, First-of-its-Kind Treatment for Rare Form of ALS

Miebo, First Prescription Eye Drop to Treat Tear Evaporation in Dry Eye Disease, Now Available

Episode 8: Stay in Sync with Innovations in Medication Decision Support

FDA Approves Sotagliflozin For Heart Failure Across Full Range of LVEF

FDA Approves First Oral Treatment for Patients With Moderate to Severe Crohn's Disease

FDA Approves Two Medications for Treatment of Schizophrenia

FDA Approves Qalsody, First-of-its-Kind Treatment for Rare Form of ALS

Miebo, First Prescription Eye Drop to Treat Tear Evaporation in Dry Eye Disease, Now Available

Related Content

Episode 8: Stay in Sync with Innovations in Medication Decision Support

The perfluorohexyloctane ophthalmic solution from Bausch + Lomb was approved by the FDA in May and will have a whole acquisition cost of $771 for a one-month supply.

FDA Approves Sotagliflozin For Heart Failure Across Full Range of LVEF

Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Approves First Oral Treatment for Patients With Moderate to Severe Crohn's Disease

The medication is broadly approved for heart failure with preserved or reduced ejection fraction.

FDA Approves Two Medications for Treatment of Schizophrenia

The approval of Rinvoq (upadacitinib) was based on the results of three clinical trials: two induction therapy studies and one maintenance study.

FDA Approves Qalsody, First-of-its-Kind Treatment for Rare Form of ALS

Otsuka America Pharmaceutical and Lundbeck’s Alify Asimtufii (aripiprazole) also was approved for maintenance monotherapy treatment of bipolar I disorder in adults.